Prognostic and Predictive Biomarkers of Therapeutic Response in Pancreatic Tumors (PACAomics)
Pancreatic cancer is among the most serious human neoplasia and the most difficult to treat.
Most patients present at diagnosis a non resectable, locally advanced or metastatic disease, with a median survival of 12 month.
The aim of this study is the identification of diagnosis biomarkers, predictive of the therapeutic response.
This project investigate the use of molecular analyses applied to pancreatic tumor cells collected by microbiopsy under ultrasound-endoscopy, and blood cells.
|Study Design:||Intervention Model: Single Group Assignment
Masking: Open Label
|Official Title:||Research for Prognostic and Predictive Biomarkers of Therapeutic Response in Pancreatic Tumors - PACAomics / IPC 2011-004|
- Biomarkers [ Time Frame: within twenty four hours ] [ Designated as safety issue: No ]Genomics, transcriptomics and proteomics analyses to determine presence or absence of biomarkers
- Histology [ Time Frame: within twenty four hours ] [ Designated as safety issue: No ]To determine the histologic characteristics of the pancreatic tumor
|Study Start Date:||February 2012|
|Estimated Study Completion Date:||February 2017|
|Estimated Primary Completion Date:||February 2017 (Final data collection date for primary outcome measure)|
Experimental: suspected pancreatic tumor
Realization of pancreatic tumor biopsy and blood samples
Procedure: suspected pancreatic tumor
Realization of pancreatic surgery to obtain tumor biopsy and blood samples to realize biomarkers analyses.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01692873
|Contact: Dominique GENRE, MD||33 (0)4 91 22 37 email@example.com|
|Contact: Agnès BOYER CHAMMARD, MD||33 (0)4 91 22 37 firstname.lastname@example.org|
|Marine GILABERT, MD||Recruiting|
|Marseille, France, 13009|
|Principal Investigator:||Marine GILABERT, MD||Institut Paoli-Calmettes|